Document:

Supply Agreement between the Company and Arch Pharmalabs, Ltd.

 EXHIBIT 10.13 
 [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
 SUPPLY AGREEMENT 
 THIS SUPPLY AGREEMENT (the “Agreement”), effective as August 1, 2006
(the “Effective Date”), is made and entered into by and between Codexis Laboratories India Private Limited, a corporation organized and existing under the laws of India and having a place of business at G-01, Prestige Loka,
7/1 Brunton Road, Bangalore – 560 025, India (“Codexis”), and Arch Pharmalabs Limited, a corporation organized and existing under the laws of India and having a place of business at H wing, 4th Floor, Tex Centre, Chandivali, Mumbai, 400072, India (“Arch”). Codexis and Arch each may be referred to herein individually as a
“Party” or collectively as the “Parties.” 
 WHEREAS, Arch has expertise and facilities for the
manufacture of bulk pharmaceutical chemicals, including without limitation the manufacture of [*], also known as TBIN, from [*], also known as hydroxynitrile, by chemical synthetic routes; and 
 WHEREAS, Codexis would like Arch to manufacture and supply TBIN at the behest of Codexis. 
 NOW, THEREFORE, in consideration of the mutual covenants and obligations set forth herein, and for other good and valuable consideration, the
receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows: 
  

	1.	DEFINITIONS 

 As used in this Agreement, the
following terms are defined as indicated: 
 1.1 “Affiliate” shall mean any entity that is controlled by, controls, or is
under common control with a Party, as the case may be. For purposes of this Section 1.1, the term “control” means (a) direct or indirect ownership of more than fifty percent (50%) of the voting interest in the entity in
question, or more than fifty percent (50%) interest in the income of the entity in question; provided, however, that if local law requires a minimum percentage of local ownership, control will be established by direct or indirect
beneficial ownership of one hundred percent (100%) of the maximum ownership percentage that may, under such local law, be owned by foreign interests, or (b) possession, directly or indirectly, of the power to direct or cause the direction
of management or policies of the entity in question (whether through ownership of securities or other ownership interests, by contract or otherwise). Notwithstanding anything to the contrary, for purposes of this Agreement, Maxygen, Inc. shall not
be considered, or deemed to be, an Affiliate of Codexis. 
 1.2 “Applicable Law” shall mean all laws, statutes, ordinances,
codes, rules, and regulations that have been enacted by a Governmental Authority and are in force as of the Effective Date or come into force during the Term, in each case to the extent that the same are applicable to the performance by the Parties
of their respective obligations under this Agreement. 

 1.3 “Certificate of Analysis” shall mean a certificate of analysis with respect to each
batch of Product in a form to be mutually agreed upon by the Parties demonstrating compliance of the Product of such batch to the Specification. 
 1.4 “Certificate of Compliance” shall mean a certificate of compliance with respect to each batch of Product in a form to be mutually agreed upon by the Parties demonstrating that such batch was manufactured in accordance
with cGMP and the requirements of this Agreement. 
 1.5 “cGMP” shall mean the current Good Manufacturing Practices
regulations and implementing guidelines and General Biological Products Standards promulgated by the FDA and published at 21 CFR §§ 210, 211 and 610, as such regulations may be amended from time to time, and by the European Commission as
set out in Directive 91/356 EEC of the Commission of the European Communities as may be amended from time to time and all relevant foreign equivalents, to the extent such regulations apply to “API intermediates” as defined in QA7 of the
Quality Guidelines of the International Conference on Harmonization. 
 1.6 “Codexis Enzyme” shall mean any proprietary
enzymes supplied by or on behalf of Codexis to Arch. 
 1.7 “Compound” shall mean [*], also known as TBIN. 
 1.8 “Confidential Information” shall mean any information of a confidential and proprietary nature disclosed by a Party to the other
Party in written form marked “confidential,” or in oral form if summarized in a writing marked “confidential” and delivered to the receiving Party within thirty (30) days after such oral disclosure. For purposes of this
Agreement, the Codexis Enzyme shall be deemed to be Confidential Information of Codexis. 
 1.9 “Direct Manufacturing Costs”
shall have the meaning set forth on Exhibit A. 
 1.10 “FDA” shall mean the U.S. Food and Drug Administration and any
successor agency. 
 1.11 “GAAP” shall mean U.S. generally accepted accounting principles, consistently applied, as in
effect from time to time. 
 1.12 “Governmental Authority” shall mean any supranational, national, regional, state or local
government, court, governmental agency, authority, board, bureau, instrumentality, or regulatory body. 
 1.13 “Initial Period
Manufacturing Costs” shall have the meaning set forth on Exhibit B. 
 1.14 “Manufacturing Facility” shall
mean Arch’s facility located at Vitalife Laboratories (a division of Arch), Village Patheri, Bilaspur-Tauru Road, Distt & Tehsil Gurgaon-Haryana, India. 
 1.15 “Material” shall mean [*], also known as hydroxynitrile. 
  

 [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 
 2 

 1.16 “Product” shall mean Compound manufactured using the Codexis Enzyme. 
 1.17 “Specification” shall mean the specifications for identity, purity and quality of the Product agreed upon by the Parties in writing
prior to the Effective Date, which may be updated from time to time in a writing signed by both Parties. 
 1.18 “Term”
shall have the meaning set forth in Section 10.1. 
 1.19 “Third Party” shall mean any party other than a Party or
an Affiliate of any Party. 
  

	2.	MATERIAL SUPPLY 

 2.1 Material Supply. For
the purpose of manufacturing Product: 
 2.1.1 Prior to the date on which Arch achieves commercial scale production of Material, Arch
may purchase from Codexis, and Codexis shall supply to Arch in accordance with the terms of a purchase order received from Arch, a quantity of Material sufficient to enable Arch to fulfill Codexis’ orders for Product, at a fee payable in Rupees
in an amount equal to [*] for each kilogram of Material. The timing and delivery of such supply by Codexis shall be consistent with the Rolling Requirement Forecast, as defined in Section 3.3.  
 2.1.2 The Parties intend to enter into a Technology Transfer and Manufacturing Agreement with respect to the manufacture of Material (the
“HN Agreement”). After the date on which Arch achieves commercial scale production of Material pursuant to the terms of the HN Agreement, Arch shall use only Material manufactured by Arch in accordance with the terms of the
HN Agreement, and shall use no other Material, in the production of Product. 
  

	3.	PRODUCT SUPPLY 

 3.1 Manufacture and Supply.
Arch shall manufacture and supply Product to Codexis or its designee in strict accordance with the Specification, cGMP, and Applicable Law. 
 3.2 Technical Supervision. During the Term, Codexis shall have the right, but not the obligation, to have at least one (1) employee of Codexis or its Affiliate present at the Manufacturing Facility in order to observe
Arch’s activities under this Agreement. 
 3.3 Rolling Requirement Forecasts. Prior to the beginning of each calendar month (M1)
during the Term, Codexis shall provide Arch with a written forecast of Codexis’ expected requirements for Product during the following twenty-four (24) months broken down by months (M1–M24), and which shall include projected order
dates, quantities, and shipping dates (“Rolling Requirement Forecast”). In each Rolling Requirement Forecast, the terms set forth for (a) the first three (3) months (months M1–M3) shall be firm orders binding on
Codexis; provided that Codexis shall have the right to increase or decrease the firm order for month M3 by 

  

 [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 
 3 

 
twenty percent (20%) in the subsequent Rolling Requirement Forecast; and (b) the subsequent twenty-one (21) months (months M4–M24) shall
be non-binding estimates. In the event Codexis requests additional quantity of Product in excess of the amount set forth for the first two (2) months, or in excess of twenty percent (20%) more than the amount set forth for the third
(3rd) month, of the Rolling Requirement Forecast, Arch shall use commercially reasonable efforts to deliver such quantities and shall promptly provide Codexis written notice in the event that Arch will not able to delivery such quantities.
 
 3.4 Purchase Orders. Products shall be ordered by Codexis by written or electronic purchase order (or by any other means
agreed by the Parties), in a form to be mutually agreed by the Parties (“Purchase Order”). Arch shall deliver to Codexis, or a Third Party designated by Codexis, the amount of Product specified in each Purchase Order no later than
the dates specified therein; provided that Arch shall not be required to deliver such amount prior to ninety (90) days after receiving such Purchase Order. The initial Purchase Order of Product by Codexis shall be provided before or with
the initial Rolling Requirement Forecast. Prior to the beginning of each month, but at least ninety (90) days prior to the earliest desired date of delivery, Codexis shall place binding Purchase Orders for Product consistent with the Rolling
Requirement Forecast. 
 3.5 Conflicts. Except as expressly set forth in Section 4.2, to the extent that there is any conflict or
inconsistency between this Agreement and any Rolling Requirement Forecast, Purchase Order, or any other document pertaining to the manufacture or supply of Product, the terms of this Agreement shall govern. 
 3.6 Manufacturing Location. All Product shall be manufactured at and supplied from the Manufacturing Facility, and Arch shall not, without
Codexis’ prior written consent, manufacture Product at or supply Product from any facility other than the Manufacturing Facility. 
 3.7 Delivery of Product. All Product shall be shipped by Arch, at Arch’s expense, by air, or as otherwise directed by Codexis, to a location designated in writing by Codexis. The Parties shall cooperate in selecting appropriate
carriers, and title and risk of loss [*]. Arch shall ship Product under appropriate packaging and storage conditions, including, for example, using Envirotainers or similar temperature-control equipment for international shipments. All Product
delivered by Arch hereunder shall have been manufactured no more than [*] prior to the date of delivery of such Product and all such deliveries shall be in whole batch increments. 
 3.8 Inspection of Product. Arch shall test and inspect all Product before shipment thereof for compliance with the Specification. Upon receipt of
each shipment of Product, Codexis, or a Third Party designated by Codexis, shall test and inspect such Product for compliance with the Specification and Purchase Orders. Acceptance by Codexis of all or part of each shipment of Product delivered by
Arch shall be subject to compliance of Product with the Specification as determined by such acceptance inspection. Codexis shall inform Arch of the result of the acceptance inspection including the judgment of acceptance or rejection of all or part
of a shipment in writing within [*] after the receipt of such shipment of Product. If Codexis fails to notify Arch of a rejection within such [*] period, the shipment of Product shall be deemed accepted by Codexis. 
  

 [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 
 4 

 3.9 Replacement of Defective Product. In the event that Arch receives a notice of rejection from
Codexis, Arch shall, at its sole expense, replace any shipment or portion thereof of such rejected Product within [*] after receiving Codexis’ written notice of rejection. Codexis shall keep such defective Products at its premises until
Arch’s instruction for return or otherwise disposal of such defective Products. Notwithstanding anything to the contrary, Arch shall have no obligation to replace any shipment of Product or part thereof pursuant to this Section 3.9 in the
event Arch can establish that such defect occurred after receipt of such shipment of Product by Codexis or a Third Party designated by Codexis. 
 3.10 Disputes. If Arch disputes Codexis’ right to reject all or part of shipment of any Product as set forth in Section 3.8, Arch shall notify Codexis within [*] after such rejection. Such dispute shall be resolved by a
Third Party, the identity of whom shall be mutually agreed upon by the Parties, and the appointment of whom shall not be unreasonably delayed by either Party. The determination of such Third Party with respect to all or part of any shipment of
Product shall be final and binding upon the Parties, but only as to the reasons given by Codexis in rejecting the shipment or part thereof and shall have no effect on any matter for which such Third Party did not make a determination. The fees and
expenses of such Third Party shall be paid by the Party against which the determination is made. Notwithstanding anything in this Section 3.10, Arch shall continue delivering Product pursuant to this Agreement during the dispute resolution
process set forth in this Section 3.10. 
 3.11 Documentation. Unless otherwise agreed in writing by the Parties, each delivery of
Product shall include a Certificate of Analysis and a Certificate of Compliance. In addition, Arch shall provide copies of such certificates directly to Codexis. Arch shall make available to Codexis and/or its Third Party customers (a) a
completed batch record for each batch of Product delivered hereunder, (b) records demonstrating appropriate transportation conditions for each shipment of Product in accordance with Section 3.7, and (c) any and all invoices and
documents evidencing delivery of product under the Indian Excise and VAT legislation required for Codexis and/or its Third Party customers to become entitled to the credit of taxes paid under such legislation, which can be offset against the output
tax liability of Codexis and/or its Third Party customers. 
 3.12 Failure to Supply Product. In the event that Arch fails to deliver
at least [*] of the amount of Product set forth in a particular Purchase Order in accordance with the terms of such Purchase Order, Codexis shall have the right to take any and all steps necessary to cover, at the sole cost and expense of Arch, any
such shortfall in the supply of Product and to modify any then-outstanding Purchase Orders without penalty. Notwithstanding the foregoing, Arch acknowledges and agrees that (a) any failure by Arch to deliver at least [*] of the amount of
Product set forth in a particular Purchase Order in accordance with the terms of such Purchase Order shall constitute a material breach of this Agreement by Arch, and (b) Codexis’ rights pursuant to this Section 3.12 shall not limit
any other rights of Codexis hereunder, including without limitation Codexis’ right to terminate this Agreement pursuant to Section 10.4.1. 
  

 [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 
 5 

	4.	CHANGES AND QUALITY CONTROL 

 4.1 Changes.
Arch shall not make any change or alteration in the Specification or in the process for the manufacture of Product (“Change”) without Codexis’ prior written consent. 
 4.1.1 In the event that Arch requests a Change and Codexis consents to such Change, Arch shall bear the costs associated with implementing such
Change, including without limitation any costs incurred in connection with testing such Change by Codexis or any Third Party laboratory designated by Codexis. 
 4.1.2 In the event that Codexis requests a Change, Codexis shall bear the costs associated with such Change, including without limitation any costs incurred in connection with testing such Change by any Third
Party laboratory 
 4.2 Manufacturing Standards and Procedures. As soon as practicable after the Effective Date, the Parties will
enter into a separate quality agreement (“Quality Agreement”) which will address, among other things, mechanisms to ensure compliance, additional audit rights, and maintenance of records. In the event of a conflict specific to an
issue of quality between the provisions of the Quality Agreement and any provisions of this Agreement, the provisions of the Quality Agreement shall govern; otherwise, the provisions of this Agreement shall govern. The Quality Agreement may be
amended from time to time by written mutual consent of the Parties in the light of changing regulatory requirements or other circumstances. Arch shall adopt and maintain quality assurance procedures and perform quality control tests designed to
ensure that all Product manufactured under this Agreement conforms to and is manufactured in accordance with the Quality Agreement. 
 4.3
Inspections of Manufacturing Facility. 
 4.3.1 Inspection by Codexis. Representatives of Codexis (a) shall upon Codexis’
request be permitted to review Arch’s QA Procedures and (b) may, during normal business hours and with reasonable advance notice, conduct a supplier audit of the Manufacturing Facility; provided that such audit shall not extend
beyond [*] and, unless deficiencies are discovered during any such audit, shall not be conducted more than [*] per calendar year. Arch shall permit representatives of Codexis to inspect the Manufacturing Facility to verify that the Product is being
manufactured and supplied in accordance with the Specification, cGMP, and Applicable Law. Arch shall promptly remedy or cause the remedy of any deficiencies that may be noted in any such inspection. Manufacturing Facility visits by Codexis shall be
conducted during normal business hours on not less than [*] advance written notice. 
 4.3.2 Inspections by Third Party Customers of
Codexis. Representatives of Codexis’ Third Party customers for Product may, during normal business hours and with reasonable advance notice, conduct a supplier audit of the Manufacturing Facility; provided that each such audit shall
not extend beyond [*] and, unless deficiencies are discovered during any such audit, shall not be conducted more than once by any particular Third Party customer in a particular calendar year. Arch shall permit such representatives to inspect the
Manufacturing Facility to verify that the Product is being manufactured and supplied in accordance with the 

  

 [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 
 6 

 
Specification, cGMP, and Applicable Law. Arch shall promptly remedy or cause the remedy of any deficiencies that may be noted in any such inspection.
Manufacturing Facility visits pursuant to this Section 4.3.2 shall be conducted during normal business hours on not less than [*] advance written notice. 
 4.3.3 Inspection by Governmental Authority. Arch agrees to provide access for Governmental Authority representatives to its facilities, including without limitation the Manufacturing Facility, for inspection at
any time. Arch shall fully cooperate with any such inspection and, within [*], shall provide Codexis with copies of all correspondence to and from any Governmental Authorities in connection with any such inspection, including without limitation any
formal reports. 
  

	5.	PAYMENTS 

 5.1 Product Transfer Fee –
Initial Period. In exchange for the supply of Product manufactured by Arch to Codexis under this Agreement, beginning on the Effective Date and continuing until [*] (the “Initial Period”), Codexis shall pay to Arch a transfer
fee, for Product supplied during the Initial Period, in accordance with this Section 5.1. For clarity, payments for Product supplied on or after [*] shall be determined in accordance with Section 5.2. 
 5.1.1 Initial Period Manufacturing Costs. Codexis shall pay to Arch an amount equal to the [*] of (a) an amount equal to [*] or (b) the
Initial Period Manufacturing Costs incurred by Arch with respect to such Product. Codexis shall determine such Initial Period Manufacturing Costs for each invoice submitted and, based on such determination, make the appropriate payment under this
Section 5.1.1 to Arch on an invoice-by-invoice basis. 
 5.1.2 Profit Share. Codexis shall pay to Arch [*] of the Profits earned
on sale of Product by Codexis during the Initial Period. For purposes of this Section 5.1.2, “Profit” shall mean an amount equal to Net Sales minus the Initial Period Manufacturing Costs, and “Net Sales” shall
mean the [*]. Notwithstanding the foregoing, for purposes of clarification, in the event that the Initial Period Manufacturing Costs equal or exceed the Net Sales for a given sale of Product, [*]. 
 5.2 Product Transfer Fee – After Initial Period. In exchange for the supply of Product
manufactured by Arch to Codexis under this Agreement, beginning on [*] and continuing until expiration or termination of this Agreement, Codexis shall pay to Arch a transfer fee, for Product supplied during such period, based on the aggregate amount
of Product supplied to Codexis in a calendar year, such fee to equal [*]. Such transfer fee for Product for such calendar year shall be based on the forecast of the aggregate amount of Product to be supplied by Codexis in such calendar year in
accordance with the most recent Rolling Forecast Requirement for such calendar year; provided that the Parties will reconcile any difference between the transfer fee actually paid based on such forecasts and the fee due based on the actual
amount of Product supplied in such calendar year no later than January 31st of the following year. Notwithstanding the foregoing, such transfer
fee shall not exceed the amounts set forth in Table 1, below. For clarity, payments for Product supplied during the Initial Period shall be determined in accordance with Section 5.1. 
  

 [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 
 7 

 Table 1 
  

			
	 Amount of Product supplied per calendar year (in [*])
	 	 Fee per [*] of Product (in U.S. dollars)

	[*]	 	[*]
	[*]	 	[*]
	[*]	 	[*]
	[*]	 	[*]

 For purposes of illustration, in the event Arch receives firm orders from Codexis for an aggregate of [*] of
Product for delivery in the first calendar year after the Initial Period, Codexis shall pay Arch an aggregate transfer fee for such Product equal to [*], such fee comprised of a transfer fee of [*] of Product (unless the [*], in which case the
transfer fee for such Product shall equal [*]). 
 5.3 Reports. Within [*] after [*], Arch shall deliver to Codexis a report setting
forth in reasonable detail the average Initial Period Manufacturing Cost or Direct Manufacturing Cost, as applicable, incurred by Arch during the previous quarter. Such Initial Period Manufacturing Cost or Direct Manufacturing Cost, as applicable,
shall serve as the basis for the calculation of the payments owed by Codexis to Arch pursuant to Section 5.1 or Section 5.2, as applicable, in [*]. 
 5.4 General Payment Terms. All payments made under this Agreement shall be made in Indian Rupees, and such payments shall be made by check or wire transfer to one or more bank accounts to be designated in
writing by the Party entitled to such payment. For purposes of calculating the exchange rate, the Parties shall use the Cross Currency rates as published in the Economic Times of India on the first market day after the date of invoice. Payments
pursuant to Section 2.1.1, Section 5.1, and Section 5.2 shall be due and payable [*] after the date of the relevant invoice delivered to Arch by Codexis or its Affiliates. 
 5.5 Taxes and Duties. 
 5.5.1
Arch shall be solely and exclusively liable for payment of all taxes, duties and levies and any interest or penalties relating thereto, including Central Excise Duty, if any, on or in connection with the manufacture and subsequent sale to
Codexis and/or its designees, of the Product sold by it under and in accordance with this Agreement and Codexis and/or its designees shall in no event be liable or responsible thereof. Arch shall be responsible for all compliance requirements under
the applicable law in this respect. 
  

 [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 
 8 

 5.5.2 Arch will claim CENVAT on all the materials/services, wherever applicable and any benefit
which may be available to or obtained by Arch pertaining to CENVAT or otherwise shall be passed on to Codexis. 
 5.5.3 It is agreed
that if any claim or dispute or litigation is raised by the Excise authorities or any other authorities in relation to the Product, Arch shall contest such claim, dispute, fine and penalty or pursue any proceedings at its own cost. Any and all
liability that may arise on that account shall be borne only by Arch. 
 5.5.4 Any duty, tax or VAT liability that may arise in the
future from disputes with the Indian Government authorities in respect of positions taken by Arch for distribution or any other disposition of the Product shall be borne by Arch. 
 5.6 Late Payment Interest. Any payment due and payable under the terms and conditions of this Agreement made after the date such payment is due
and payable shall bear interest as of the day after the date such payment was due and payable and shall continue to accrue such interest until such payment is made at a rate equal to the prime rate as reported by Federal Reserve Bank of New York,
located in New York, New York, United States of America, as of the date such payment was due and payable. 
 5.7 Audit Rights. Arch
shall permit Codexis to have access, during regular business hours and upon at least ten (10) days’ written notice, to Arch’s records and books, to the extent necessary to (a) determine the accuracy of Initial Period
Manufacturing Costs or Direct Manufacturing Costs, as applicable, reported by Arch within the three (3) year period immediately preceding such an audit and (b) verify that Arch has not sold or transferred any Product or Codexis Enzymes to
any Third Party in violation of the terms and conditions of this Agreement. If such examination results in a determination that Initial Period Manufacturing Costs or Direct Manufacturing Costs, as applicable, have been overstated leading to any
overpayment by Codexis to Arch, such overpayments shall be promptly refunded plus interest in accordance with Section 5.5. If such examination reveals that Arch has sold or transferred Product and/or Codexis Enzyme to any Third Party in
violation of the terms and conditions of this Agreement, Codexis shall have the right to terminate this Agreement pursuant to Section 10.4.2. The fees and expenses of such accountant shall be paid by Codexis, unless the examination results in a
determination that (i) Initial Period Manufacturing Costs or Direct Manufacturing Costs, as applicable, have been overstated, or that payments have been overpaid, by more than five percent (5%) for the period examined, and/or
(ii) Product and/or Codexis Enzyme have been sold or transferred to any Third Party in violation of the terms and conditions of this Agreement, in which case Arch shall pay all reasonable costs and expenses incurred by Codexis in the course of
making such determination, including the fees and expenses of such accountant. 
  

	6.	CONFIDENTIALITY 

 6.1 In General. Each Party
(the “Disclosing Party”) has provided to the other Party (the “Receiving Party”) prior to the Effective Date, and in connection with this Agreement may 

  

 [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 
 9 

 
in the future provide to the other Party, Confidential Information, including but not limited to the Disclosing Party’s know-how, invention disclosures,
patent applications, proprietary materials and/or technologies, economic information, business or research strategies, trade secrets, and material embodiments thereof. 
 6.2 Non-Disclosure and Non-Use. The Receiving Party shall maintain the Confidential Information of the Disclosing Party in confidence, shall not disclose such Confidential Information to any Third Party, and
shall not use such Confidential Information for any purpose except as expressly permitted under the terms and conditions of this Agreement. Notwithstanding the previous sentence, the Receiving Party may disclose the Confidential Information of the
Disclosing Party to its employees, agents, consultants, and professional, scientific, medical, and legal advisors who have a reasonable need to know such Confidential Information; provided that any such person to whom disclosure is made is
bound by obligations of non-disclosure and non-use no less restrictive then those set forth herein. The Receiving Party shall take the same degree of care that the Receiving Party uses to protect its own confidential and proprietary information of a
similar nature and importance, but in no event shall such care be less than reasonable care. 
 6.3 Exceptions. The obligations of
non-disclosure and non-use under Section 6.2 will not apply as to particular Confidential Information of a Disclosing Party to the extent that such Confidential Information: (a) is at the time of receipt, or thereafter becomes, through no
fault of the Receiving Party, published or publicly known or available; (b) is known by the Receiving Party or its Affiliates at the time of receiving such information, as evidenced by records; (c) is hereafter furnished to the Receiving
Party or its Affiliates by a Third Party without breach of a duty to the Disclosing Party; or (d) is independently discovered or developed by the Receiving Party or its Affiliates without use of, application of, access to, or reference to
Confidential Information of the Disclosing Party, as evidenced by records. 
 6.4 Disclosure Required by Law. Disclosure of
Confidential Information shall not be precluded if such disclosure (a) is in response to a valid order of a court or other governmental body or (b) is required by law or regulation; provided, however, that the Receiving Party
shall first have given reasonable prior notice to the Disclosing Party and shall have made a reasonable effort to obtain a protective order, or to cooperate with the Disclosing Party’s efforts, as applicable, to obtain a protective order
limiting the extent of such disclosure and requiring that the Confidential Information so disclosed be used only for the purposes for which such order was issued or as required by such law or regulation. 
 6.5 Remedies. The Receiving Party agrees that its obligations under this Article 6 are necessary and reasonable to protect the Disclosing
Party’s business interests and that the unauthorized disclosure or use of Confidential Information of a Disclosing Party will cause irreparable harm and significant injury, the degree of which may be difficult to ascertain. The Receiving Party
further acknowledges and agrees that in the event of any actual or threatened breach of this Article 6, the Disclosing Party may have no adequate remedy at law and, accordingly, that the Disclosing Party will have the right to seek an immediate
injunction enjoining any breach or threatened breach of this Article 6, as well as the right to pursue any and all other rights and remedies available at law or in equity for such breach or threatened breach. 
  

 [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 
 10 

 6.6 Agreement Terms; Press Release. The terms and conditions of this Agreement shall be
Confidential Information of the Parties, and subject to the terms of this Article 6. Notwithstanding the foregoing, upon or after the execution of this Agreement, the Parties shall issue a press release in a form and manner acceptable to each other.

 6.7 Survival. All obligations of non-disclosure and non-use imposed pursuant to the terms and conditions of this Article 6 shall
survive expiration or termination of this Agreement and continue in full force and effect for a period of seven (7) years after the effective date of such expiration or such termination. 
  

	7.	REPRESENTATIONS, WARRANTIES AND COVENANTS 

 7.1
Representations and Warranties of Codexis. Codexis hereby represents and warrants that as of the Effective Date: 
 7.1.1 Codexis
is a corporation organized under the laws of India and is authorized to do business to the extent necessary to fulfill its obligations hereunder; 
 7.1.2 Codexis has the full right and authority to enter into this Agreement, and no consent or authorization not obtained prior to the Effective Date is necessary to be obtained; and 
 7.1.3 To the knowledge of Codexis, there is no material impediment that would prevent, preclude, or otherwise inhibit its ability to perform its
obligations, under this Agreement. 
 7.2 Representations and Warranties of Arch. Arch hereby represents and warrants that as of the
Effective Date: 
 7.2.1 Arch is a corporation organized under the laws of India and is authorized to do business to the extent
necessary to fulfill its obligations hereunder; 
 7.2.2 Arch has the full right and authority to enter into this Agreement, and no
consent or authorization not obtained prior to the Effective Date is necessary to be obtained; 
 7.2.3 Arch has obtained all
licenses, authorizations, and permissions necessary or requisite in law for the meeting and performing its obligations under this Agreement and all such licenses, authorizations, and permissions are in full force and effect; 
 7.2.4 There is no material impediment that would prevent, preclude or otherwise inhibit its ability to perform its obligations under this
Agreement; and 
 7.2.5 Arch’s manufacturing facilities and all manufacturing facilities utilized by it are registered with the
appropriate Governmental Authorities and in compliance with all applicable Governmental Authority standards and Applicable Law. 
  

 [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 
 11 

 7.3 Covenants of Arch. Arch hereby covenants that: 
 7.3.1 All Product supplied by Arch hereunder shall (a) conform to the Specification; (b) be free of defects in materials or workmanship
under normal use and service and be fit for the purpose for which such Product is intended; (c) not be adulterated or misbranded within the meaning of the U.S. Food, Drug and Cosmetic Act; (d) be manufactured and supplied in accordance
with cGMP; and (e) be manufactured and supplied in accordance with the Quality Agreement; 
 7.3.2 Arch undertakes to keep all
licenses, authorizations, and permissions necessary or requisite in law for the meeting and performing its obligations under this Agreement in full force and effect during the term of this Agreement; 
 7.3.3 Arch will use Material and Codexis Enzyme solely for the purpose of manufacture of Product and will not supply Material or Codexis Enzyme to
any Third Party; 
 7.3.4 Arch will not supply Product to any Third Party except as otherwise expressly designated in writing by
Codexis or its Affiliate; 
 7.3.5 As long as Arch or its successor is manufacturing Product at the behest of Codexis or its
Affiliate, Arch’s manufacturing facilities and all manufacturing facilities utilized by it will be registered with the appropriate Governmental Authorities and in compliance with all applicable Governmental Authority standards and Applicable
Law; 
 7.3.6 Arch will not use the Codexis Enzymes otherwise than as required in the manufacture of Product at the behest of Codexis
or its Affiliate; 
 7.3.7 Arch will use packing for the Product, including without limitation cartons, ship cases, and pallets, of
industry standard strength in order to maintain the quality of the Product during normal transportation and storage; and 
 7.3.8 Arch
shall at all times strictly comply with all applicable laws, rules, and regulations from time to time in force including, without prejudice to the generality of the foregoing, the provisions of the Drugs & Cosmetics Act 1940, prevailing
Drugs Price Control Order, Central Excises Act 1944, The Industries (Development & Regulation) Act, 1951 and labour welfare legislation and the rules, regulations and notifications made or issued thereunder, relating to due and proper
performance of its duties and obligations under this Agreement. In the event of Arch committing a breach of this clause, it shall indemnify and keep indemnified Codexis of, from and against all claims, demands, actions, proceedings, fines, penalties
and expenses of whatsoever nature made or brought against, sustained or incurred by Codexis and paid for, arising out of or as a result of such breach by Arch. 
 7.4 For clarity, no right, title, or interest is granted by Codexis to Arch in, to, or under the Codexis Enzymes. 
 7.5 Limitation of Warranties. EXCEPT AS SPECIFICALLY SET FORTH IN THIS ARTICLE 7, NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY 

  

 [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 
 12 

 
OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION, ANY WARRANTY OF MERCHANTABILITY, ANY WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE OR USE, ANY
WARRANTY OF NON-INFRINGEMENT, OR ANY OTHER STATUTORY WARRANTY. 
  

	8.	INDEMNIFICATION 

 8.1 Arch Indemnification.
Arch shall indemnify, defend, and hold Codexis, and its directors, officers, employees, agents, and Affiliates, harmless from and against all claims, demands, damages, liabilities, losses, costs, and expenses, including without limitation
attorney’s fees (collectively, “Claims”) resulting from or arising out of (a) any material breach by Arch of any of Arch’s representations, warranties, or covenants delivered to Codexis under Article 7, (b) the
development, testing, manufacture, use, exportation, storage, handling, transportation, distribution, or any other disposition of any Product made using the Codexis Enzymes by Arch or any Affiliate of Arch, or (c) the imposition of any tax or
duty described in Section 5.5 on Codexis or any Affiliate of Codexis; provided, however, that Arch’s indemnification obligations under this Section 8.1 shall not apply (i) to the extent that any such Claim arises
out of any breach by Codexis of any of Codexis’ representations or warranties delivered to Arch under Article 7, (ii) to any claim arising out of Codexis’ negligence or willful misconduct, or (iii) to the extent such Claims are
the responsibility of Codexis under Section 8.2. 
 8.2 Codexis Indemnification. Codexis shall indemnify, defend, and hold Arch,
and its directors, officers, employees, agents, and Affiliates, harmless from and against all Claims resulting from or arising out of (a) any material breach by Codexis of any of Codexis’ representations or warranties delivered to Arch
under Article 7 or (b) the development, testing, manufacture, use, sale, offer for sale, importation, exportation, storage, handling, transportation, distribution, or any other disposition of any Product by Codexis or any Affiliate of Codexis;
provided, however, that Codexis’ indemnification obligations under this Section 8.2 shall not apply (i) to the extent that any such Claim arises out of any breach by Arch of any of Arch’s representations, warranties
or covenants under Article 7, (ii) to any claim arising out of Arch’s negligence or willful misconduct, or (iii) to the extent such Claims are the responsibility of Arch under Section 8.1. 
 8.3 Procedure. For purposes of this Article 8, the indemnified Party shall give prompt written notice to the indemnifying Party of any suits,
claims, or demands by Third Parties or the indemnified Party that may give rise to any Claim for which indemnification may be required under this Article 8; provided, however, that failure to give such notice shall not relieve the
indemnifying Party of its obligation to provide indemnification hereunder except if and to the extent that such failure materially affects the ability of the indemnifying Party to defend the applicable suit, claim, or demand. The indemnifying Party
shall be entitled to assume the defense and control of any such suit, claim, or demand of any Third Party at its own cost and expense; provided, however, that the indemnified Party shall have the right to be represented by its own
counsel at its own cost in such matters. In the event that the indemnifying Party declines to or fails to timely assume control of any such suit, claim, or demand, the indemnified Party shall be entitled to assume such control, conduct the defense
of, and settle such suit, claim, or 

  

 [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 
 13 

 
action, all at the sole cost and expense of the indemnifying Party. Neither the indemnifying Party nor the indemnified Party shall settle or dispose of any
such matter in any manner that would adversely affect the rights or interests of the other Party without the prior written consent of the other Party, which shall not be unreasonably withheld or delayed. Each Party shall cooperate with the other
Party and its counsel in the course of the defense of any such suit, claim, or demand, such cooperation to include without limitation using reasonable efforts to provide or make available documents, information, and witnesses. 
  

	9.	DISPUTE RESOLUTION 

 9.1 Exclusive Dispute
Resolution Mechanism. The Parties agree that the procedures set forth in this Article 9 shall be the exclusive mechanism for resolving any dispute, controversy, or claim (collectively, “Disputes”) between the Parties that may
arise from time to time pursuant to this Agreement relating to any Party’s rights and/or obligations hereunder that cannot be resolved through good faith negotiation between the Parties. 
 9.2 Arbitration. 
 9.2.1 Any
and all unresolved Disputes, except as set forth in Section 9.3 or Section 9.4, shall be exclusively and finally resolved by binding arbitration. 
 9.2.2 Any arbitration concerning a Dispute shall be conducted in New York, New York, United States of America, unless otherwise agreed to by the Parties in writing. Each and any arbitration shall be
administered by the American Arbitration Association (the “AAA”), and shall be conducted in accordance with the Commercial Arbitration Rules of the AAA (the “Rules”), as such Rules may be amended from time to time.

 9.2.3 Within ten (10) days after receipt of an arbitration notice from a Party, the Parties shall attempt in good faith to
agree on a single neutral arbitrator with relevant industry experience to conduct the arbitration. If the Parties do not agree on a single neutral arbitrator within ten (10) days after receipt of an arbitration notice, each Party shall select
one (1) arbitrator and the two (2) Party-selected arbitrators shall select a third arbitrator with relevant industry experience to constitute a panel of three (3) arbitrators to conduct the arbitration in accordance with the Rules. In
the event that only one of the Parties selects an arbitrator, then such arbitrator shall be entitled to act as the sole arbitrator to resolve the Dispute or any all unresolved issues subject to the arbitration. Each and every arbitrator of the
arbitration panel conducting the arbitration must and shall agree to render an opinion within twenty (20) days after the final hearing before the panel. 
 9.2.4 The decision or award of the arbitrator(s) shall be final, binding, and incontestable and may be used as a basis for judgment thereon in any jurisdiction. To the full extent permissible under Applicable
Law, the Parties hereby expressly agree to waive the right to appeal from the decision of the arbitrator(s), there shall be no appeal to any court or other authority (government or private) from the decision of the arbitrator(s), and the Parties
shall not dispute nor question the validity of such decision or award before any regulatory or other 

  

 [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 
 14 

 
authority in any jurisdiction where enforcement action is taken by the Party in whose favor the decision or award is rendered, except in the case of fraud.
The arbitrator(s) shall, upon the request of any Party, issue a written opinion of the findings of fact and conclusions of law and shall deliver a copy to each of the Parties. Each Party shall bear its own costs and attorney’s fees, and the
Parties shall equally bear the fees, costs, and expenses of the arbitrator(s) and the arbitration proceedings; provided, however, that the arbitrator(s) may exercise discretion to award costs, including attorney’s fees, to the
prevailing Party. Without limiting any other remedies that may be available under applicable law, the arbitrator(s) shall have no authority to award provisional remedies of any nature whatsoever, or punitive, special, consequential, or any other
similar form of damages. 
 9.3 Preliminary Injunctions. Notwithstanding anything in this Agreement to the contrary, a Party may seek
a temporary restraining order or a preliminary injunction from any court of competent jurisdiction in order to prevent immediate and irreparable injury, loss, or damage on a provisional basis, pending the decision of the arbitrator(s) on the
ultimate merits of any Dispute. 
 9.4 Patent Disputes. Notwithstanding anything in this Agreement to the contrary, any and all issues
regarding the scope, construction, validity, and enforceability of one or more patents shall be determined in a court of competent jurisdiction under the local patent laws of the jurisdictions having issued the patent or patents in question.

 9.5 Confidentiality. All proceedings and decisions of the arbitrator(s) shall be deemed Confidential Information of each of the
Parties, and shall be subject to Article 6 of this Agreement. 
  

	10.	TERM AND TERMINATION 

 10.1 Term. The term of
this Agreement shall commence on the Effective Date and continue in full force and effect until [*], unless and until terminated at an earlier date in accordance with Section 10.2, Section 10.3, or Section 10.4 (the
“Term”). 
 10.2 Termination upon Notice. Codexis may, at its sole discretion, terminate this Agreement at any time
upon [*] written notice to Arch. 
 10.3 Termination for Insolvency. To the extent permitted under Applicable Law, a Party may
terminate this Agreement upon written notice to the other Party on or after the occurrence of any of the following events: (a) the appointment of a trustee, receiver or custodian for all or substantially all of the property of the other Party,
or for any lesser portion of such property, if the result materially and adversely affects the ability of the other Party to fulfill its obligations hereunder, which appointment is not dismissed within sixty (60) days, (b) the
determination by a court or tribunal of competent jurisdiction that the other Party is insolvent such that a Party’s liabilities exceed the fair market value of its assets, (c) the filing of a petition for relief in bankruptcy by the other
Party on its own behalf, or the filing of any such petition against the other Party if the proceeding is not dismissed or withdrawn within sixty (60) days thereafter, (d) an assignment by the other Party for the benefit of creditors, or
(e) the dissolution or liquidation of the other Party. 
  

 [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 
 15 

 10.4 Termination for Cause. 
 10.4.1 If a Party materially breaches any term or condition of this Agreement, the other Party may notify the breaching Party in writing of such
breach, setting forth the nature of the breach in reasonable detail. If the breaching Party fails to cure such breach within [*] after the receipt of the foregoing notice from the non-breaching Party, the non-breaching Party may terminate this
Agreement effective immediately upon a second written notice to the breaching Party. 
 10.4.2 Notwithstanding Section 10.4.1, if
Arch materially breaches any covenant contained in Section 7.3, Codexis shall have the right, but not the obligation, to terminate this Agreement effective immediately upon written notice to Arch. 
 10.5 Effect of Expiration or Termination. 
 10.5.1 Expiration of this Agreement for any reason shall not release any Party from any obligation that has accrued prior to the effective date of such expiration. 
 10.5.2 Upon expiration or termination of this Agreement for any reason, Arch shall cease use of all Codexis Enzymes. 
 10.5.3 Termination of this Agreement for any reason shall not (a) release any Party from any obligation that has accrued prior to the
effective date of such termination (including the obligation to pay amounts accrued and due under this Agreement prior to the termination date but which are unpaid or become payable thereafter), (b) preclude any Party from claiming any other
damages, compensation, or relief that it may be entitled to upon such termination, or (c) terminate any right to obtain performance of any obligation provided for in this Agreement that shall survive termination. 
 10.5.4 Upon expiration or termination of this Agreement by Codexis for any reason, each Party shall promptly return, or destroy and provide
written certification of such destruction, any and all Confidential Information of the other Parties in such first Party’s possession or control at the time of such termination. 
 10.6 Survival. Articles 1, 5, 6, 8, 9, and 11 and Sections 3.5, 7.3, 7.4, 7.5, 10.5, and 10.6 shall survive expiration or termination of this
Agreement, as applicable.  
  

	11.	MISCELLANEOUS 

 11.1 Further Assurances. From
time to time on and after the Effective Date, each Party shall at the reasonable request of the other Party (a) deliver to the other Party such records, data, or other documents consistent with the provisions of this Agreement;
(b) execute, and deliver or cause to be delivered, all assignments, consents, documents or further instruments of 

  

 [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 
 16 

 
transfer or license; and (c) take or cause to be taken all other actions as such other Party may reasonably deem necessary or desirable in order for
such Party to obtain the full benefits of this Agreement and the transactions contemplated hereby. 
 11.2 Limitation of Liability.
EXCEPT WITH RESPECT TO UNAUTHORIZED EXPLOITATION OF CODEXIS’ INTELLECTUAL PROPERTY RIGHTS OR BREACH OF THE CONFIDENTIALITY OBLIGATION UNDER THIS AGREEMENT, IN NO EVENT SHALL EITHER PARTY BE LIABLE FOR INCIDENTAL, CONSEQUENTIAL, INDIRECT,
PUNITIVE, EXEMPLARY, OR SPECIAL DAMAGES OF THE OTHER PARTY ARISING OUT OF OR RELATED TO THIS AGREEMENT, HOWEVER CAUSED, UNDER ANY THEORY OF LIABILITY. 
 11.3 Governing Law. This Agreement shall be governed by, and construed and interpreted in accordance with, the laws of India. 
 11.4 Force Majeure. No Party shall be held responsible for any delay or failure in performance hereunder caused by strikes, embargoes, unexpected government requirements, civil or military authorities, acts of
God, earthquake, or by the public enemy or other causes reasonably beyond such Party’s control and without such Party’s fault or negligence; provided that the affected Party notifies the unaffected Party as soon as reasonably
possible and resumes performance hereunder as soon as reasonably possible following cessation of such force majeure event; and provided further that no such delay or failure in performance shall continue for more than three (3) months.
In the event that a delay or failure in performance by a Party under this Section 11.4 continues longer than three (3) months, the other Party may terminate this Agreement in accordance with the terms and conditions of Section 10.4.

 11.5 Independent Contractors. 
 11.5.1 Nothing in this Agreement shall constitute or be deemed to or is intended to constitute Arch as an agent of Codexis. It is hereby expressly agreed and declared that Arch shall not at any time: 
 a. enter into a contract in the name of or purporting to be made on behalf of Codexis unless to the extent as may be authorized under any agreement
entered into between the Parties; 
 b. by any act, pledge the credit of Codexis or impose or attempt to impose any contractual obligations
on Codexis; and 
 c. either in its own office, factories or depots or on invoices, bill heads or letter papers or any other place or by any
other means, oral or written, make any statement to the effect or representation calculated or liable to induce others to believe that it is the agent of Codexis. 
 11.5.2 Arch shall not, except with the prior written approval of Codexis, sub-contract or delegate to any other person, firm or company the whole or any part of the manufacture or packing of the Product under
this Agreement or assign any of its rights, duties or obligations thereunder. Arch shall continue to be liable to Codexis in respect of its obligations under this Agreement not withstanding such sub-contract or delegation. 
  

 [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 
 17 

 11.5.3 Nothing contained herein shall be deemed to constitute a partnership between the Parties.

 11.6 Assignment. This Agreement is binding upon and inures to the benefit of the Parties, and to their permitted successors and
assigns. The Parties agree that their rights and obligations under this Agreement may not be transferred or assigned to a Third Party without the prior written consent of the other Parties hereto. Notwithstanding the foregoing, Codexis shall have
the right to transfer or assign its rights and obligations under this Agreement, without consent, to a successor to all or substantially all of its business or assets relating to this Agreement whether by operation of law, sale, merger, or otherwise
in a manner such that Codexis will remain liable and responsible for the performance and observance of all its duties and obligations hereunder. Any assignment not in conformance with this Section 11.6 shall be null, void, and of no legal
effect.  
 11.7 Notices. Any notice, report, communication, or consent required or permitted by this Agreement shall be in
writing and shall be sent (a) by prepaid registered or certified mail, return receipt requested, (b) by overnight express delivery service by a nationally recognized courier, or (c) via confirmed facsimile or telecopy, followed within
five (5) days by a copy mailed in the preceding manner, addressed to the other Party at the address shown below or at such other address as such Party gives notice hereunder. Such notice will be deemed to have been given when delivered or, if
delivery is not accomplished by some fault of the addressee, when tendered. 
  

							
	If to Arch:	  	Arch Pharmalabs Limited	  	
		  	H wing, 4th Floor	  	
		  	Tex Centre	  	
		  	Off Saki Vihar Road	  	
		  	Chandivali, Mumbai- 400072	  	
		  	India	  	
		  	Attn: [*]	  	
		  	Facsimile: [*]	  	

  

 [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 
 18 

							
	If to Codexis:	  	Codexis Laboratories India Private Limited	  	
		  	G-01, Prestige Loka	  	
		  	7/1 Brunton Road	  	
		  	Bangalore – 560 025, India	  	
		  	Attn: [*]	  	
			
		  	Facsimile:	  	

 11.8 Severability. If any provision of any provision of this Agreement shall be found by a
court to be void, invalid, or unenforceable, the same shall be reformed to comply with Applicable Law or stricken if not so conformable, so as not to affect the validity or enforceability of this Agreement; provided that no such reformation
or striking shall be effective if the result materially changes the economic benefit of this Agreement to any Party. In the event that any provision of this Agreement becomes or is declared by a court of competent jurisdiction to be void, invalid,
or unenforceable, and reformation or striking of such provision would materially change the economic benefit of this Agreement to any Party, the Parties shall modify such provision in accordance with Section 11.9 to obtain a legal, valid, and
enforceable provision and provide an economic benefit to the Parties that most nearly effects the Parties’ intent on entering into this Agreement. 
 11.9 Modifications; Waivers. This Agreement may not be altered, amended, supplemented, or modified in any way except by a writing signed by each Party. The failure of a Party to enforce any rights or provisions
of the Agreement shall not be construed to be a waiver of such rights or provisions, or a waiver by such Party to thereafter enforce such rights or provision or any other rights or provisions hereunder. 
 11.10 Entire Agreement. The Parties acknowledge that this Agreement, including the exhibit attached hereto sets forth the entire agreement and
understanding of the Parties as to the subject matter hereof, and supersedes all prior and contemporaneous discussions, agreements, and writings with respect hereto with respect to the subject matter hereof. No trade customs, courses of dealing or
courses of performance by the Parties shall be relevant to modify, supplement, or explain any term(s) used in this Agreement. 
 11.11 No
Third Party Beneficiaries. This Agreement is neither expressly nor impliedly made for the benefit of any party other than those executing it. 
 11.12 Interpretation. 
 (a) Captions and Headings. The captions and headings of clauses contained in this Agreement
preceding the text of the articles, sections, subsections, and paragraphs hereof are inserted solely for convenience and ease of reference only and shall not constitute any part of this Agreement, or have any effect on its interpretation or
construction. 
 (b) Singular and Plural. All references in this Agreement to the singular shall include the plural where applicable,
and all references to gender shall include both genders and the neuter. 
  

 [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 
 19 

 (c) Articles, Sections, and Subsections. Unless otherwise specified, references in this Agreement
to any article shall include all sections, subsections, and paragraphs in such article; references in this Agreement to any section shall include all subsections and paragraphs in such section; and references in this Agreement to any subsection
shall include all paragraphs in such subsection. 
 (d) Days. All references to days in this Agreement shall mean calendar days,
unless otherwise specified. 
 (e) Ambiguities. The Parties jointly drafted this Agreement. Ambiguities and uncertainties in this
Agreement, if any, shall not be interpreted against any Party, irrespective of which Party may be deemed to have caused the ambiguity or uncertainty to exist. 
 11.13 Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original and all of which together shall constitute one instrument. 
 [Signature page follows] 
  

 [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 
 20 

 IN WITNESS WHEREOF, the Parties have executed this Agreement by their respective duly authorized representatives
as of the Effective Date. 
  

			
	CODEXIS LABORATORIES INDIA PRIVATE LIMITED
	(“Codexis”)
		
	By:	 	 /s/ Alan Shaw

	Name:	 	Alan Shaw
	Title:	 	Director
	
	ARCH PHARMALABS LIMITED
	(“Arch”)
		
	By:	 	 /s/ Ajit Kamath

	Name:	 	Ajit Kamath
	Title:	 	CMD

 [Signature Page of Supply Agreement] 

 Exhibit A 
 Direct Manufacturing Costs 
 [*] 
  

 [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 
 1 

 Exhibit B 
 Initial Period Manufacturing Costs 
 [*] 
  

 [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 
 1Enzyme License and Supply Agreement between the Company and Arch Pharmalabs, Ltd

 EXHIBIT 10.14 
 [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
 ENZYME LICENSE AND SUPPLY AGREEMENT 
 THIS ENZYME LICENSE AND SUPPLY AGREEMENT (the “Agreement”), effective as
of August 1, 2006 (the “Effective Date”), is made and entered into by and between Codexis, Inc., a Delaware corporation, having a place of business at 200 Penobscot Drive, Redwood City, California 94063, USA
(“Codexis”), and Arch Pharmalabs Limited, a corporation organized and existing under the laws of India, having a place of business at H wing, 4th Floor, Tex Centre, Chandivali, Mumbai, 400072, India (“Arch”). Codexis and Arch each may be referred to herein individually as a “Party,” or collectively as the
“Parties.” 
 WHEREAS, Arch has expertise and facilities for the manufacture of bulk pharmaceutical chemicals,
including without limitation the manufacture of TBIN from [*], also known as hydroxynitrile, by chemical synthetic routes; 
 WHEREAS,
Codexis owns proprietary rights in certain chemical synthesis and biocatalysis process technology, and possesses certain valuable business and/or technical knowledge, information, and/or expertise, relating to an enzymatically catalyzed
manufacturing process for [*], also known as TBIN; and 
 WHEREAS, Arch would like to use proprietary technology and enzymes of
Codexis in the manufacture TBIN. 
 NOW, THEREFORE, in consideration of the mutual covenants and obligations set forth herein, and for
other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows: 
  

	1.	DEFINITIONS 

 As used in this Agreement, the
following terms are defined as indicated: 
 1.1 “Affiliate” shall mean any entity that is controlled by, controls, or
is under common control with a Party, as the case may be. For purposes of this Section 1.1, the term “control” means (a) direct or indirect ownership of more than fifty percent (50%) of the voting interest in the entity in
question, or more than fifty percent (50%) interest in the income of the entity in question; provided, however, that if local law requires a minimum percentage of local ownership, control will be established by direct or indirect
beneficial ownership of one hundred percent (100%) of the maximum ownership percentage that may, under such local law, be owned by foreign interests, or (b) possession, directly or indirectly, of the power to direct or cause the direction
of management or policies of the entity in question (whether through ownership of securities or other ownership interests, by contract or otherwise). Notwithstanding anything to the contrary, for purposes of this Agreement, Maxygen, Inc. shall not
be considered, or deemed to be, an Affiliate of Codexis. 

 1.2 “Applicable Law” shall mean all laws, statutes, ordinances, codes, rules, and
regulations that have been enacted by a Governmental Authority and are in force as of the Effective Date or come into force during the Term, in each case to the extent that the same are applicable to the performance by the Parties of their
respective obligations under this Agreement. 
 1.3 “Codexis Enzyme” shall mean any proprietary enzymes supplied by or on
behalf of Codexis to Arch. 
 1.4 “Codexis Know-How” shall mean technology, information, expertise, know-how, and/or trade
secrets Controlled by Codexis relating to the manufacture of Compound that is not within the Codexis Patent Rights but is necessary or useful for making Compound.  
 1.5 “Codexis Patent Rights” shall mean any and all patent rights Controlled by Codexis that are necessary or useful in the manufacture of Compound.  
 1.6 “Codexis Technology” shall mean the Codexis Know-How, the Codexis Patent Rights, and any discovery, invention, contribution, method,
finding, or improvement, whether or not patentable, and all related know-how, that is conceived, reduced to practice, or otherwise developed by Arch, either solely or jointly with Codexis and/or a Third Party, during the Term that relate to Product,
Codexis Technology, and/or Codexis Enzymes. 
 1.7 “Compound” shall mean [*], also known as TBIN. 
 1.8 “Confidential Information” shall mean any information of a confidential and proprietary nature disclosed by a Party to the
other Party in written form marked “confidential,” or in oral form if summarized in a writing marked “confidential” and delivered to the receiving Party within thirty (30) days after such oral disclosure. For purposes of
this Agreement, the Codexis Enzyme shall be deemed to be Confidential Information of Codexis. 
 1.9 “Control” shall mean,
with respect to an item or an intellectual property right, possession of the ability, whether arising by ownership or license, to grant a license or sublicense as provided for in this Agreement under such item or right without violating the terms of
any written agreement with any Third Party. 
 1.10 “Governmental Authority” shall mean any supranational, national,
regional, state or local government, court, governmental agency, authority, board, bureau, instrumentality, or regulatory body. 
 1.11
“Product” shall mean Compound manufactured using the Codexis Technology and/or the Codexis Enzyme. 
 1.12 “Term”
shall have the meaning set forth in Section 10.1. 
 1.13 “Territory” shall mean India. 
  

 [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 
 2 

 1.14 “Third Party” shall mean any party other than a Party or an Affiliate of any Party.

  

	2.	LICENSE GRANTS 

 2.1 Grant of Rights to Arch.
Subject to the terms and conditions of this Agreement, Codexis hereby grants to Arch a non-exclusive, royalty-free right and license, with no right to grant sublicense rights, under the Codexis Technology solely to manufacture Product at the
behest of Codexis and/or its Affiliates in the Territory. For the purpose of clarification, Arch shall have no right to use, import, export, offer to sell, sell, market, or otherwise commercialize Codexis Technology or Product. 
 2.2 No Other Rights. Except as expressly provided herein, no right, title, or interest is granted by Codexis to Arch in, to, or under the Codexis
Technology or the Codexis Enzymes. 
  

	3.	CODEXIS ENZYME SUPPLY 

 3.1 Codexis Enzyme
Supply. Arch shall exclusively purchase from Codexis, and Codexis shall supply to Arch, a quantity of Codexis Enzyme sufficient to enable Arch solely to fulfill Codexis’ or its Affiliate’s orders for Product. The timing and delivery of
such supply shall be consistent with the Rolling Requirement Forecast, as defined in Section 3.2. 
 3.2 Rolling Requirement
Forecasts. Prior to the beginning of each calendar month (M1) during the Term, Arch shall provide Codexis with a written forecast of Arch’s expected requirements for Codexis Enzyme during the following twenty-four (24) months broken
down by months (M1–M24), and which shall include projected order dates, quantities, and shipping dates (“Rolling Requirement Forecast”). In each Rolling Requirement Forecast, the terms set forth for (a) the first three
(3) months (months M1–M3) shall be firm orders binding on Arch; provided that Arch shall have the right to increase or decrease the firm order for month M3 by twenty percent (20%) in the subsequent Rolling Requirement Forecast;
and (b) the subsequent twenty-one (21) months (months M4–M24) shall be non-binding estimates. In the event Arch requests additional quantity of Codexis Enzyme in excess of the amount set forth for the first two (2) months, or in
excess of twenty percent (20%) more than the amount set forth for the third (3rd) month, of the Rolling Requirement Forecast, Codexis shall use commercially reasonable efforts to deliver such quantities and shall promptly provide Arch
written notice in the event that Codexis will not able to delivery such quantities.  
 3.3 Purchase Orders. Codexis
Enzyme shall be ordered by Arch by written or electronic purchase order (or by any other means agreed by the Parties), in a form to be mutually agreed by the Parties (“Purchase Order”). Codexis shall deliver to Arch the amount of
Codexis Enzyme specified in each Purchase Order no later than the dates specified therein; provided that Codexis shall not be required to deliver such amount prior to ninety (90) days after receiving 

  

 [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 
 3 

 
such Purchase Order. The initial Purchase Order of Codexis Enzyme by Arch shall be provided before or with the initial Rolling Requirement Forecast. Prior to
the beginning of each month, but at least ninety (90) days prior to the earliest desired date of delivery, Arch shall place binding Purchase Orders for Codexis Enzyme consistent with the Rolling Requirement Forecast. 
 3.4 Conflicts. To the extent that there is any conflict or inconsistency between this Agreement and any Rolling Requirement Forecast, Purchase
Order, or any other document pertaining to the manufacture or supply of Codexis Enzyme, the terms of this Agreement shall govern. For clarity, no term or condition added by Arch to a Purchase Order, other than quantity of Codexis Enzyme ordered and
delivery date requested, shall be binding on Codexis unless such term or condition is specifically agreed to by Codexis in writing. 
 3.5 Delivery of Codexis Enzyme. All Codexis Enzyme shall be shipped by Codexis, at Codexis’ expense, by air, or as otherwise directed by Arch, to Arch’s manufacturing facility located at Vitalife Laboratories (a
division of Arch), Village Patheri, Bilaspur-Tauru Road, Distt & Tehsil Gurgaon-Haryana, India. The Parties shall cooperate in selecting appropriate carriers, and title and risk of loss shall pass to Arch upon delivery by Codexis to such
carrier(s). Codexis shall ship Codexis Enzyme under appropriate packaging and storage conditions, including, for example, using Envirotainers or similar temperature-control equipment for international shipments. 
 3.6 Inspection of Codexis Enzyme. Upon receipt of each shipment of Codexis Enzyme, Arch shall test and inspect such Codexis Enzyme for
compliance with the Purchase Orders corresponding to such shipment. Arch shall inform Codexis of the result of the acceptance inspection including the judgment of acceptance or rejection of all or part of a shipment in writing within [*] after the
receipt of such shipment of Codexis Enzyme. If Arch fails to notify Codexis of a rejection within such [*] period, the shipment of Codexis Enzyme shall be deemed accepted by Arch. 
 3.7 Replacement of Defective Codexis Enzyme. In the event that Codexis receives a notice of rejection from Arch, Codexis shall, at its sole
expense, replace any shipment of such rejected Codexis Enzyme within [*] after receiving Arch’s written notice of rejection. Arch shall keep such defective Codexis Enzyme at its premises until Codexis’ instruction for return or otherwise
disposal of such defective Codexis Enzyme. Notwithstanding anything to the contrary, Codexis shall have no obligation to replace any shipment of Codexis Enzyme or part thereof pursuant to this Section 3.7 in the event Codexis can establish that
such defect occurred after receipt of such shipment of Codexis Enzyme by Arch. 
 3.8 Disputes. If Codexis disputes Arch’s
right to reject all or part of shipment of any Codexis Enzyme as set forth in Section 3.6, Codexis shall notify Arch within [*] after receipt of Arch’s written notice of such rejection. Such dispute shall be resolved by a Third Party, the
identity of whom shall be mutually agreed upon by the Parties, and the appointment of whom shall not be unreasonably delayed by either Party. The determination of such Third Party with respect to all or part of any shipment of Codexis Enzyme shall
be final and binding upon the Parties, but only as to the reasons given by Arch in rejecting the shipment or part thereof and shall have no effect on any matter for which such Third Party did not make a determination. The 

  

 [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 
 4 

 
fees and expenses of such Third Party shall be paid by the Party against which the determination is made. Notwithstanding anything in this Section 3.8,
Codexis shall continue delivering Codexis Enzyme pursuant to the terms of this Agreement during the dispute resolution process set forth in this Section 3.8. 
  

	4.	PAYMENTS 

 4.1 Codexis Enzyme Transfer Fee.
In exchange for the supply of Codexis Enzyme to Arch pursuant to Section 3.1, Arch shall pay Codexis a transfer fee equal to [*] Codexis Enzyme transferred to Arch; provided that such price shall increase based on increases in
manufacturing cost incurred by Codexis with respect to the applicable Codexis Enzyme. 
 4.2 General Payment Terms. All
payments made under this Agreement shall be made in U.S. dollars, and such payments shall be made by check or wire transfer to one or more bank accounts to be designated in writing by the Party entitled to such payment. Payments pursuant to
Section 4.1 shall be due and payable [*] after the date of the relevant invoice. 
 4.3 Taxes and Duties. 
 4.3.1 Arch shall be solely and exclusively liable for payment of all taxes, duties and levies and any interest or penalties relating thereto,
including Service Tax, if any, on or in connection with the transfer of Codexis Technology and import of Codexis Enzyme by it under and in accordance with this Agreement and Codexis shall in no event be liable or responsible thereof. Arch shall be
responsible for all compliance requirements under the applicable law in this respect. 
 4.3.2 It is agreed that if any claim or
dispute or litigation is raised by the concerned authorities in relation to the transfer of Codexis Technology and import of Codexis Enzyme, Arch shall contest such claim, dispute, fine and penalty or pursue any proceedings at its own cost. Any and
all liability that may arise on that account shall be borne only by Arch. 
 4.3.3 Any duty, tax, service tax or VAT, liability that
may arise in the future from disputes with the Indian Government authorities in respect of positions taken by Arch for transfer of technology and import of Codexis Enzyme shall be borne by Arch. 
 4.4 Late Payment Interest. Any payment due and payable under the terms and conditions of this Agreement made after the date such payment is
due and payable shall bear interest as of the day after the date such payment was due and payable and shall continue to accrue such interest until such payment is made at a rate equal to the prime rate as reported by Federal Reserve Bank of New
York, located in New York, New York, United States of America, as of the date such payment was due and payable. 
  

 [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 
 5 

	5.	CONFIDENTIALITY 

 5.1 In General. Each
Party (the “Disclosing Party”) has provided to the other Party (the “Receiving Party”) prior to the Effective Date, and in connection with this Agreement may in the future provide to the other Party, Confidential
Information, including but not limited to the Disclosing Party’s know-how, invention disclosures, patent applications, proprietary materials and/or technologies, economic information, business or research strategies, trade secrets, and material
embodiments thereof. 
 5.2 Non-Disclosure and Non-Use. The Receiving Party shall maintain the Confidential Information of the
Disclosing Party in confidence, shall not disclose such Confidential Information to any Third Party, and shall not use such Confidential Information for any purpose except as expressly permitted under the terms and conditions of this Agreement.
Notwithstanding the previous sentence, the Receiving Party may disclose the Confidential Information of the Disclosing Party to its employees, agents, consultants, and professional, scientific, medical, and legal advisors who have a reasonable need
to know such Confidential Information; provided that any such person to whom disclosure is made is bound by obligations of non-disclosure and non-use no less restrictive then those set forth herein. The Receiving Party shall take the same
degree of care that the Receiving Party uses to protect its own confidential and proprietary information of a similar nature and importance, but in no event shall such care be less than reasonable care. 
 5.3 Exceptions. The obligations of non-disclosure and non-use under Section 5.2 will not apply as to particular Confidential
Information of a Disclosing Party to the extent that such Confidential Information: (a) is at the time of receipt, or thereafter becomes, through no fault of the Receiving Party, published or publicly known or available; (b) is known by
the Receiving Party or its Affiliates at the time of receiving such information, as evidenced by records; (c) is hereafter furnished to the Receiving Party or its Affiliates by a Third Party without breach of a duty to the Disclosing Party; or
(d) is independently discovered or developed by the Receiving Party or its Affiliates without use of, application of, access to, or reference to Confidential Information of the Disclosing Party, as evidenced by records. 
 5.4 Disclosure Required by Law. Disclosure of Confidential Information shall not be precluded if such disclosure (a) is in response to
a valid order of a court or other governmental body or (b) is required by law or regulation; provided, however, that the Receiving Party shall first have given reasonable prior notice to the Disclosing Party and shall have made a
reasonable effort to obtain a protective order, or to cooperate with the Disclosing Party’s efforts, as applicable, to obtain a protective order limiting the extent of such disclosure and requiring that the Confidential Information so disclosed
be used only for the purposes for which such order was issued or as required by such law or regulation. 
 5.5 Remedies. The
Receiving Party agrees that its obligations under this Article 5 are necessary and reasonable to protect the Disclosing Party’s business interests and that the unauthorized disclosure or use of Confidential Information of a Disclosing Party
will cause irreparable harm and significant injury, the degree of which may be difficult to ascertain. The Receiving Party further acknowledges and agrees that in the event of any actual or threatened 

  

 [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 
 6 

 
breach of this Article 5, the Disclosing Party may have no adequate remedy at law and, accordingly, that the Disclosing Party will have the right to seek an
immediate injunction enjoining any breach or threatened breach of this Article 5, as well as the right to pursue any and all other rights and remedies available at law or in equity for such breach or threatened breach. 
 5.6 Agreement Terms; Press Release. The terms and conditions of this Agreement shall be Confidential Information of the Parties, and subject to
the terms of this Article 5. Notwithstanding the foregoing, upon or after the execution of this Agreement, the Parties shall issue a press release in a form and manner acceptable to each other. 
 5.7 Survival. All obligations of non-disclosure and non-use imposed pursuant to the terms and conditions of this Article 5 shall survive
expiration or termination of this Agreement and continue in full force and effect for a period of seven (7) years after the effective date of such expiration or such termination. 
  

	6.	INTELLECTUAL PROPERTY 

 6.1 Ownership.
 
 6.1.1 As between the Parties, subject only to the licenses set forth in Article 2, Codexis shall retain all right, title,
and interest in and to the Codexis Patent Rights, Codexis Know-How, and Codexis Enzymes. 
 6.1.2 Arch hereby assigns to Codexis all
its right, title, and interest in, to, and under any and all any discovery, invention, contribution, method, finding, or improvement, whether or not patentable, and all related know-how, that is conceived, reduced to practice, or otherwise developed
by Arch, either solely or jointly with Codexis and/or a Third Party, during the Term that relate to Product, Codexis Technology and/or Codexis Enzymes. 
 6.2 Filing, Prosecution, and Maintenance. Codexis, at Codexis’ expense, shall have the right, but not the obligation, to file applications for and to control the prosecution and maintenance of (a) the
Codexis Patent Rights and (b) any patents or patent applications claiming any Codexis Technology. 
 6.3 Enforcement. 

6.3.1 At any time during the Term, if a Party determines that a Third Party is or may be infringing any patent, or may have misappropriated any
other right, within the Codexis Technology, if any, the Party making such determination shall promptly provide written notice to the other Party thereof. 
 6.3.2 Codexis, at Codexis’s expense, shall have the right, but not the obligation, to enforce all rights (a) in the Codexis Technology; and (b) with respect to any and all intellectual property
covering any Codexis Technology. 
  

 [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 
 7 

 6.3.3 In the event that Codexis enforces a right pursuant to this Section 6.3, Arch and its
Affiliates, if applicable, shall cooperate fully with Codexis in such enforcement, including without limitation by joining as a party plaintiff and executing such documents as Codexis may reasonably request. 
 6.4 Allocation of Recovery. Any recovery awarded by a court of competent jurisdiction or final resort in an unreversed, unappealed, or
unappealable decision or judgment from an action by Codexis to enforce any right within the Codexis Technology and/or any and all intellectual property covering any Codexis Technology shall be first applied to reimburse Codexis’ unreimbursed
expenses, and then Arch’s unreimbursed expenses, including without limitation reasonable attorney’s fees and court costs. Any remaining amount of such damages or other monetary awards shall then be applied between the Parties in such
action or proceeding on a pro rata basis based upon the Parties’ respective out-of-pocket expenses directly associated with such action or proceeding. 
  

	7.	REPRESENTATIONS, WARRANTIES AND COVENANTS 

 7.1
Representations and Warranties of Codexis. Codexis hereby represents and warrants that as of the Effective Date: 
 7.1.1 Codexis
has the full right and authority to enter into this Agreement, and no consent or authorization not obtained prior to the Effective Date is necessary to be obtained; 
 7.1.2 Codexis Controls the Codexis Patent Rights; 
 7.1.3 Codexis has not granted any right,
license, or interest in, to, or under the Codexis Patent Rights that is materially inconsistent with the rights granted to Arch hereunder; 
 7.1.4 To the knowledge of Codexis, without investigation of any particular matter, there are no material actions, suits, investigations, claims, or proceedings pending or threatened relating to the Codexis Patent Rights; 

7.1.5 To the knowledge of Codexis, there is no material infringement of any right within the Codexis Patent Rights by any Third Party; and

 7.1.6 To the knowledge of Codexis, there is no material impediment that would prevent, preclude, or otherwise inhibit its ability
to grant the rights and licenses granted, or to perform its obligations, under this Agreement. 
 7.2 Representations and
Warranties of Arch. Arch hereby represents and warrants that as of the Effective Date: 
 7.2.1 Arch is a corporation organized
under the laws of India and is authorized to do business to the extent necessary to fulfill its obligations hereunder; 
  

 [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 
 8 

 7.2.2 Arch has the full right and authority to enter into this Agreement, and no consent or
authorization not obtained prior to the Effective Date is necessary to be obtained; 
 7.2.3 Arch has obtained all licenses,
authorizations, and permissions necessary or requisite in law for the meeting and performing its obligations under this Agreement and all such licenses, authorizations, and permissions are in full force and effect; 
 7.2.4 There is no material impediment that would prevent, preclude or otherwise inhibit its ability to perform its obligations under this
Agreement; and 
 7.2.5 Arch’s manufacturing facilities and all manufacturing facilities utilized by it are registered with the
appropriate Governmental Authorities and in compliance with all applicable Governmental Authority standards and Applicable Law. 
 7.3
Covenants of Arch. Arch hereby covenants that: 
 7.3.1 Arch will use Codexis Technology and/or Codexis Enzyme solely for the
purpose of manufacture of Product and will not supply Codexis Enzyme to any Third Party; 
 7.3.2 Arch will not use the Codexis
Technology and/or Codexis Enzyme otherwise than as required in the manufacture of Product solely at the behest of Codexis or its Affiliate; 
 7.3.3 Arch undertakes to keep all licenses, authorizations, and permissions necessary or requisite in law for the meeting and performing its obligations under this Agreement in full force and effect during the term of this Agreement;
and 
 7.3.4 Arch shall at all times strictly comply with all applicable laws, rules, and regulations from time to time in force
including, without prejudice to the generality of the foregoing, the provisions of the Drugs & Cosmetics Act 1940, prevailing Drugs Price Control Order, Central Excises Act 1944, The Industries (Development & Regulation) Act, 1951
and labour welfare legislation and the rules, regulations and notifications made or issued thereunder, relating to due and proper performance of its duties and obligations under this Agreement. In the event of Arch committing a breach of this
clause, it shall indemnify and keep indemnified Codexis of, from and against all claims, demands, actions, proceedings, fines, penalties and expenses of whatsoever nature made or brought against, sustained or incurred by Codexis and paid for,
arising out of or as a result of such breach by Arch. 
 7.4 Limitation of Warranties. EXCEPT AS SPECIFICALLY SET FORTH IN THIS
ARTICLE 7, NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION, ANY WARRANTY OF MERCHANTABILITY, ANY WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE OR USE, ANY WARRANTY OF NON-INFRINGEMENT,
OR ANY OTHER STATUTORY WARRANTY. 
  

 [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 
 9 

	8.	INDEMNIFICATION 

 8.1 Arch
Indemnification. Arch shall indemnify, defend, and hold Codexis, and its directors, officers, employees, agents, and Affiliates, harmless from and against all claims, demands, damages, liabilities, losses, costs, and expenses, including without
limitation attorney’s fees (collectively, “Claims”) resulting from or arising out of (a) any material breach by Arch of any of Arch’s representations, warranties, or covenants delivered to Codexis under Article 7,
(b) the development, testing, manufacture, use, exportation, storage, handling, transportation, distribution, or any other disposition of any Product made using the Codexis Technology and/or Codexis Enzyme by Arch or any Affiliate of Arch, or
(c) the imposition of any tax or duty described in Section 4.3 on Codexis or any Affiliate of Codexis; provided, however, that Arch’s indemnification obligations under this Section 8.1 shall not apply (i) to
the extent that any such Claim arises out of any breach by Codexis of any of Codexis’ representations or warranties delivered to Arch under Article 7, (ii) to any claim arising out of Codexis’ negligence or willful misconduct, or
(iii) to the extent such Claims are the responsibility of Codexis under Section 8.2. 
 8.2 Codexis Indemnification.
Codexis shall indemnify, defend, and hold Arch, and its directors, officers, employees, agents, and Affiliates, harmless from and against all Claims resulting from or arising out of (a) any material breach by Codexis of any of Codexis’
representations or warranties delivered to Arch under Article 7 or (b) the development, testing, manufacture, use, sale, offer for sale, importation, exportation, storage, handling, transportation, distribution, or any other disposition of any
Product by Codexis or any Affiliate of Codexis; provided, however, that Codexis’ indemnification obligations under this Section 8.2 shall not apply (i) to the extent that any such Claim arises out of any breach by Arch
of any of Arch’s representations, warranties or covenants under Article 7, (ii) to any claim arising out of Arch’s negligence or willful misconduct, or (iii) to the extent such Claims are the responsibility of Arch under
Section 8.1. 
 8.3 Procedure. For purposes of this Article 8, the indemnified Party shall give prompt written notice to
the indemnifying Party of any suits, claims, or demands by Third Parties or the indemnified Party that may give rise to any Claim for which indemnification may be required under this Article 8; provided, however, that failure to give
such notice shall not relieve the indemnifying Party of its obligation to provide indemnification hereunder except if and to the extent that such failure materially affects the ability of the indemnifying Party to defend the applicable suit, claim,
or demand. The indemnifying Party shall be entitled to assume the defense and control of any such suit, claim, or demand of any Third Party at its own cost and expense; provided, however, that the indemnified Party shall have the right
to be represented by its own counsel at its own cost in such matters. In the event that the indemnifying Party declines to or fails to timely assume control of any such suit, claim, or demand, the indemnified Party shall be entitled to assume such
control, conduct the defense of, and settle such suit, claim, or action, all at the sole cost and expense of the indemnifying Party. Neither the indemnifying Party nor the indemnified Party shall settle or dispose of any such matter in any manner
that would adversely affect the rights or interests of the other Party without the prior written consent of the other Party, which shall not be unreasonably withheld or delayed. Each Party shall cooperate with the other Party and its counsel in the
course of the defense of any such suit, claim, or demand, such cooperation to include without limitation using reasonable efforts to provide or make available documents, information, and witnesses. 
  

 [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 
 10 

	9.	DISPUTE RESOLUTION 

 9.1 Exclusive Dispute
Resolution Mechanism. The Parties agree that the procedures set forth in this Article 9 shall be the exclusive mechanism for resolving any dispute, controversy, or claim (collectively, “Disputes”) between the Parties that may
arise from time to time pursuant to this Agreement relating to any Party’s rights and/or obligations hereunder that cannot be resolved through good faith negotiation between the Parties. 
 9.2 Arbitration. 
 9.2.1 Any
and all unresolved Disputes, except as set forth in Section 9.3 or Section 9.4, shall be exclusively and finally resolved by binding arbitration. 
 9.2.2 Any arbitration concerning a Dispute shall be conducted in New York, New York, United States of America, unless otherwise agreed to by the Parties in writing. Each and any arbitration shall be
administered by the American Arbitration Association (the “AAA”), and shall be conducted in accordance with the Commercial Arbitration Rules of the AAA (the “Rules”), as such Rules may be amended from time to time.

 9.2.3 Within ten (10) days after receipt of an arbitration notice from a Party, the Parties shall attempt in good faith to
agree on a single neutral arbitrator with relevant industry experience to conduct the arbitration. If the Parties do not agree on a single neutral arbitrator within ten (10) days after receipt of an arbitration notice, each Party shall select
one (1) arbitrator and the two (2) Party-selected arbitrators shall select a third arbitrator with relevant industry experience to constitute a panel of three (3) arbitrators to conduct the arbitration in accordance with the Rules. In
the event that only one of the Parties selects an arbitrator, then such arbitrator shall be entitled to act as the sole arbitrator to resolve the Dispute or any all unresolved issues subject to the arbitration. Each and every arbitrator of the
arbitration panel conducting the arbitration must and shall agree to render an opinion within twenty (20) days after the final hearing before the panel. 
 9.2.4 The decision or award of the arbitrator(s) shall be final, binding, and incontestable and may be used as a basis for judgment thereon in any jurisdiction. To the full extent permissible under Applicable
Law, the Parties hereby expressly agree to waive the right to appeal from the decision of the arbitrator(s), there shall be no appeal to any court or other authority (government or private) from the decision of the arbitrator(s), and the Parties
shall not dispute nor question the validity of such decision or award before any regulatory or other authority in any jurisdiction where enforcement action is taken by the Party in whose favor the decision or award is rendered, except in the case of
fraud. The arbitrator(s) shall, upon the request of any Party, issue a written opinion of the findings of fact and conclusions of law and shall deliver a copy to each of the Parties. Each Party shall bear its own costs and attorney’s 

  

 [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 
 11 

 
fees, and the Parties shall equally bear the fees, costs, and expenses of the arbitrator(s) and the arbitration proceedings; provided, however,
that the arbitrator(s) may exercise discretion to award costs, including attorney’s fees, to the prevailing Party. Without limiting any other remedies that may be available under applicable law, the arbitrator(s) shall have no authority to
award provisional remedies of any nature whatsoever, or punitive, special, consequential, or any other similar form of damages. 
 9.3
Preliminary Injunctions. Notwithstanding anything in this Agreement to the contrary, a Party may seek a temporary restraining order or a preliminary injunction from any court of competent jurisdiction in order to prevent immediate and
irreparable injury, loss, or damage on a provisional basis, pending the decision of the arbitrator(s) on the ultimate merits of any Dispute. 
 9.4 Patent Disputes. Notwithstanding anything in this Agreement to the contrary, any and all issues regarding the scope, construction, validity, and enforceability of one or more patents shall be determined in a court of
competent jurisdiction under the local patent laws of the jurisdictions having issued the patent or patents in question. 
 9.5
Confidentiality. All proceedings and decisions of the arbitrator(s) shall be deemed Confidential Information of each of the Parties, and shall be subject to Article 5 of this Agreement. 
  

	10.	TERM AND TERMINATION 

 10.1 Term. The
term of this Agreement shall commence on the Effective Date and continue in full force and effect until [*], unless and until terminated at an earlier date in accordance with Section 10.2, Section 10.3, or Section 10.4 (the
“Term”). 
 10.2 Termination upon Notice. Codexis may, at its sole discretion, terminate this Agreement at any
time upon [*] written notice to Arch. 
 10.3 Termination for Insolvency. To the extent permitted under Applicable Law, a Party
may terminate this Agreement upon written notice to the other Party on or after the occurrence of any of the following events: (a) the appointment of a trustee, receiver or custodian for all or substantially all of the property of the other
Party, or for any lesser portion of such property, if the result materially and adversely affects the ability of the other Party to fulfill its obligations hereunder, which appointment is not dismissed within [*], (b) the determination by a
court or tribunal of competent jurisdiction that the other Party is insolvent such that a Party’s liabilities exceed the fair market value of its assets, (c) the filing of a petition for relief in bankruptcy by the other Party on its own
behalf, or the filing of any such petition against the other Party if the proceeding is not dismissed or withdrawn within [*] thereafter, (d) an assignment by the other Party for the benefit of creditors, or (e) the dissolution or
liquidation of the other Party. 
  

 [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 
 12 

 10.4 Termination for Cause. 
 10.4.1 If a Party materially breaches any term or condition of this Agreement, the other Party may notify the breaching Party in writing of such
breach, setting forth the nature of the breach in reasonable detail. If the breaching Party fails to cure such breach within [*] after the receipt of the foregoing notice from the non-breaching Party, the non-breaching Party may terminate this
Agreement effective immediately upon a second written notice to the breaching Party. 
 10.4.2 Notwithstanding Section 10.4.1, if
Arch materially breaches any covenant contained in Section 7.3, Codexis shall have the right, but not the obligation, to terminate this Agreement effective immediately upon written notice to Arch. 
 10.5 Effect of Expiration or Termination. 
 10.5.1 Expiration of this Agreement for any reason shall not release any Party from any obligation that has accrued prior to the effective date of such expiration. 
 10.5.2 Upon expiration or termination of this Agreement for any reason, all rights and license granted by Codexis to Arch under this Agreement
shall terminate and Arch shall cease use of all Codexis Technology and Codexis Enzymes. 
 10.5.3 Termination of this Agreement for
any reason shall not (a) release any Party from any obligation that has accrued prior to the effective date of such termination (including the obligation to pay amounts accrued and due under this Agreement prior to the termination date but
which are unpaid or become payable thereafter), (b) preclude any Party from claiming any other damages, compensation, or relief that it may be entitled to upon such termination, or (c) terminate any right to obtain performance of any
obligation provided for in this Agreement that shall survive termination. 
 10.5.4 Upon expiration or termination of this Agreement
by Codexis for any reason, each Party shall promptly return, or destroy and provide written certification of such destruction, any and all Confidential Information of the other Parties in such first Party’s possession or control at the time of
such termination. 
 10.6 Survival. Articles 1, 5, 6, 8, 9, and 11 and Sections 3.4, 4.2, 4.3, 4.4, 7.3, 7.4, 10.5, and 10.6 shall
survive expiration or termination of this Agreement, as applicable.  
  

	11.	MISCELLANEOUS 

 11.1 Further
Assurances. From time to time on and after the Effective Date, each Party shall at the reasonable request of the other Party (a) deliver to the other Party such records, data, or other documents consistent with the provisions of this
Agreement; (b) execute, and deliver or cause to be delivered, all assignments, consents, documents or further instruments of transfer or license; and (c) take or cause to be taken all other actions as such other Party may reasonably deem
necessary or desirable in order for such Party to obtain the full benefits of this Agreement and the transactions contemplated hereby. 
  

 [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 
 13 

 11.2 Limitation of Liability. EXCEPT WITH RESPECT TO UNAUTHORIZED EXPLOITATION OF CODEXIS’
INTELLECTUAL PROPERTY RIGHTS OR BREACH OF THE CONFIDENTIALITY OBLIGATIONS UNDER THIS AGREEMENT, IN NO EVENT SHALL EITHER PARTY BE LIABLE FOR INCIDENTAL, CONSEQUENTIAL, INDIRECT, PUNITIVE, EXEMPLARY, OR SPECIAL DAMAGES OF THE OTHER PARTY ARISING OUT
OF OR RELATED TO THIS AGREEMENT, HOWEVER CAUSED, UNDER ANY THEORY OF LIABILITY. 
 11.3 Governing Law. This Agreement shall be
governed by, and construed and interpreted in accordance with, the internal laws of the State of New York, United States of America, without giving effect to any choice of law rule that would cause the application of the laws of any jurisdiction
other than the internal laws of the State of New York to the rights and duties of the Parties. 
 11.4 Force Majeure. No Party
shall be held responsible for any delay or failure in performance hereunder caused by strikes, embargoes, unexpected government requirements, civil or military authorities, acts of God, earthquake, or by the public enemy or other causes reasonably
beyond such Party’s control and without such Party’s fault or negligence; provided that the affected Party notifies the unaffected Party as soon as reasonably possible and resumes performance hereunder as soon as reasonably possible
following cessation of such force majeure event; and provided further that no such delay or failure in performance shall continue for more than three (3) months. In the event that a delay or failure in performance by a Party under this
Section 11.4 continues longer than three (3) months, the other Party may terminate this Agreement in accordance with the terms and conditions of Section 10.4. 
 11.5 Independent Contractors. 
 11.5.1 Nothing in this Agreement shall constitute or be deemed to or is intended to constitute Arch as an agent of Codexis. It is hereby expressly agreed and declared that Arch shall not at any time: 
 a. enter into a contract in the name of or purporting to be made on behalf of Codexis unless to the extent as may be authorized under any agreement
entered into between the Parties; 
 b. by any act, pledge the credit of Codexis or impose or attempt to impose any contractual obligations
on Codexis; and 
 c. either in its own office, factories or depots or on invoices, bill heads or letter papers or any other place or by any
other means, oral or written, make any statement to the effect or representation calculated or liable to induce others to believe that it is the agent of Codexis. 
  

 [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 
 14 

 11.5.2 Arch shall not, except with the prior written approval of Codexis, sub-contract or delegate
to any other person, firm or company the whole or any part of the manufacture or packing of the Product under this Agreement or assign any of its rights, duties or obligations thereunder. Arch shall continue to be liable to Codexis in respect of its
obligations under this Agreement not withstanding such sub-contract or delegation. 
 11.5.3 Nothing contained herein shall be deemed
to constitute a partnership between the Parties. 
 11.6 Assignment. This Agreement is binding upon and inures to the benefit of the
Parties, and to their permitted successors and assigns. The Parties agree that their rights and obligations under this Agreement may not be transferred or assigned to a Third Party without the prior written consent of the other Parties hereto.
Notwithstanding the foregoing, Codexis shall have the right to transfer or assign its rights and obligations under this Agreement, without consent, to a successor to all or substantially all of its business or assets relating to this Agreement
whether by operation of law, sale, merger, or otherwise in a manner such that Codexis will remain liable and responsible for the performance and observance of all its duties and obligations hereunder. Any assignment not in conformance with this
Section 11.6 shall be null, void, and of no legal effect. 
 11.7 Notices. Any notice, report, communication, or consent
required or permitted by this Agreement shall be in writing and shall be sent (a) by prepaid registered or certified mail, return receipt requested, (b) by overnight express delivery service by a nationally recognized courier, or
(c) via confirmed facsimile or telecopy, followed within five (5) days by a copy mailed in the preceding manner, addressed to the other Party at the address shown below or at such other address as such Party gives notice hereunder. Such
notice will be deemed to have been given when delivered or, if delivery is not accomplished by some fault of the addressee, when tendered. 
  

			
	If to Arch:	  	Arch Pharmalabs Limited
		  	H wing, 4th Floor
		  	Tex Centre
		  	Off Saki Vihar Road
		  	Chandivali, Mumbai- 400072
		  	India
		  	Attn: [*]
		  	Facsimile: [*]

  

 [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 
 15 

			
	If to Codexis:	  	Codexis, Inc.
		  	200 Penobscot Drive
		  	Redwood City, California 94063
		  	USA
		  	Attn: [*]
		  	Facsimile: [*]

 11.8 Severability. If any provision of any provision of this Agreement shall be
found by a court to be void, invalid, or unenforceable, the same shall be reformed to comply with Applicable Law or stricken if not so conformable, so as not to affect the validity or enforceability of this Agreement; provided that no such
reformation or striking shall be effective if the result materially changes the economic benefit of this Agreement to any Party. In the event that any provision of this Agreement becomes or is declared by a court of competent jurisdiction to be
void, invalid, or unenforceable, and reformation or striking of such provision would materially change the economic benefit of this Agreement to any Party, the Parties shall modify such provision in accordance with Section 11.9 to obtain a
legal, valid, and enforceable provision and provide an economic benefit to the Parties that most nearly effects the Parties’ intent on entering into this Agreement. 
 11.9 Modifications; Waivers. This Agreement may not be altered, amended, supplemented, or modified in any way except by a writing signed by each Party. The failure of a Party to enforce any rights or
provisions of the Agreement shall not be construed to be a waiver of such rights or provisions, or a waiver by such Party to thereafter enforce such rights or provision or any other rights or provisions hereunder. 
 11.10 Entire Agreement. The Parties acknowledge that this Agreement, including the exhibit attached hereto sets forth the entire agreement
and understanding of the Parties as to the subject matter hereof, and supersedes all prior and contemporaneous discussions, agreements, and writings with respect hereto with respect to the subject matter hereof. No trade customs, courses of dealing
or courses of performance by the Parties shall be relevant to modify, supplement, or explain any term(s) used in this Agreement. 
 11.11 No Third Party Beneficiaries. This Agreement is neither expressly nor impliedly made for the benefit of any party other than those executing it. 
 11.12 Interpretation. 
 (a)
Captions and Headings. The captions and headings of clauses contained in this Agreement preceding the text of the articles, sections, subsections, and paragraphs hereof are inserted solely for convenience and ease of reference only and shall not
constitute any part of this Agreement, or have any effect on its interpretation or construction. 
  

 [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 
 16 

 (b) Singular and Plural. All references in this Agreement to the singular shall include the plural
where applicable, and all references to gender shall include both genders and the neuter. 
 (c) Articles, Sections, and Subsections.
Unless otherwise specified, references in this Agreement to any article shall include all sections, subsections, and paragraphs in such article; references in this Agreement to any section shall include all subsections and paragraphs in such
section; and references in this Agreement to any subsection shall include all paragraphs in such subsection. 
 (d) Days. All
references to days in this Agreement shall mean calendar days, unless otherwise specified. 
 (e) Ambiguities. The Parties jointly
drafted this Agreement. Ambiguities and uncertainties in this Agreement, if any, shall not be interpreted against any Party, irrespective of which Party may be deemed to have caused the ambiguity or uncertainty to exist. 
 11.13 Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original and all of which together
shall constitute one instrument. 
 [Signature Page Follows] 
  

 [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 
 17 

 IN WITNESS WHEREOF, the Parties have executed this Agreement by their respective duly authorized representatives
as of the Effective Date. 
  

			
	CODEXIS, INC.
	(“Codexis”)
		
	By:	 	 /s/ Robert S. Breuil

	Name:	 	Robert S. Breuil
	Title:	 	CFO
	
	ARCH PHARMALABS LIMITED
	(“Arch”)
		
	By:	 	 /s/ Ajit Kamath

	Name:	 	Ajit Kamath
	Title:	 	CMD

 [Signature Page to Enzyme License and Supply Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00140-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00140-of-00352.parquet"}]]